Pred Forte®
prednisolone acetate ophthalmic suspension 1%
Clinical Snapshot
Prednisolone acetate 1% is the benchmark high-potency topical corticosteroid in ophthalmic practice. It provides robust anti-inflammatory effect and excellent anterior chamber penetration, making it the standard of care for anterior uveitis and significant postoperative inflammation.
Mechanism of Action
Prednisolone acetate is a potent corticosteroid that inhibits phospholipase A2, suppressing the arachidonic acid cascade and reducing prostaglandin, leukotriene, and cytokine production. The acetate ester form provides superior corneal penetration compared to prednisolone sodium phosphate.
Common Clinical Applications
- Anterior uveitis (first-line)
- Postoperative inflammation following intraocular surgery
- Significant ocular surface and anterior segment inflammation
- Episcleritis and scleritis (adjunctive)
Typical Dosing Principles
Dosing is indication-dependent. For anterior uveitis: typically every 1–2 hours initially, tapering based on clinical response. Shake well before use.
Dosing information is provided for educational purposes. Always consult current prescribing information for specific dosing protocols.
Important Precautions
- IOP elevation is a significant risk — monitor IOP with any course exceeding 2 weeks.
- Prolonged use increases risk of posterior subcapsular cataract.
- Contraindicated in most viral, fungal, and mycobacterial ocular infections.
- Steroid responders may develop significant IOP elevation within days of initiation.
Clinical Pearls
- The acetate ester form provides superior anterior chamber penetration compared to phosphate formulations — critical for anterior uveitis management.
- Shake well before use; inadequate mixing results in inconsistent drug delivery.
- IOP monitoring is essential with any extended course.
- Tapering should be guided by clinical response — premature taper risks rebound inflammation.
Commonly Associated Disease States
Select any disease state to explore its full entry in the Disease State Library.
Anterior Uveitis
HLA-B27 association is present in a significant proportion of cases; recurrent anterior uveitis warrants systemic evaluation for associated conditions including ankylosing spondylitis, reactive arthritis, and inflammatory bowel disease.
Dry Eye Disease
One of the most prevalent conditions in optometric practice; a leading cause of patient dissatisfaction and reduced quality of life, with significant implications for contact lens wear, surgical candidacy, and systemic disease management.
Episcleritis
Generally benign and self-limiting; distinguished from scleritis by the absence of deep boring pain and the blanching response to phenylephrine; systemic association is less common than in scleritis.
This entry is an educational reference designed to support clinical reasoning and therapeutic awareness. It does not constitute medical advice, establish a standard of care, or replace individualized patient assessment. Clinicians should consult current prescribing information before initiating any therapy.